{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T04:17:31Z","timestamp":1744345051395,"version":"3.40.4"},"reference-count":21,"publisher":"Impact Journals, LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"DOI":"10.18632\/aging.206238","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T18:32:02Z","timestamp":1744309922000},"source":"Crossref","is-referenced-by-count":0,"title":["Impact of Factor Xa inhibitors on cardiovascular events in older patients with nonvalvular atrial fibrillation"],"prefix":"10.18632","author":[{"given":"Masahiko","family":"Takahashi","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Kagawa Prefectural Central Hospital, Takamatsu, Kagawa 760-8557, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Hyogo Medical University, Nishinomiya, Hyogo 663-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryu","family":"Tsushima","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kagawa Prefectural Central Hospital, Takamatsu, Kagawa 760-8557, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Sudo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kagawa Prefectural Central Hospital, Takamatsu, Kagawa 760-8557, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kagawa Prefectural Central Hospital, Takamatsu, Kagawa 760-8557, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Sogo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kagawa Prefectural Central Hospital, Takamatsu, Kagawa 760-8557, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatomo","family":"Ozaki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kagawa Prefectural Central Hospital, Takamatsu, Kagawa 760-8557, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Okawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kagawa Prefectural Central Hospital, Takamatsu, Kagawa 760-8557, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"d124","DOI":"10.1136\/bmj.d124","article-title":"Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study.","volume":"34","author":"Torp-Pedersen","year":"2011","journal-title":"BMJ"},{"key":"2","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr488","article-title":"Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.","volume":"3","author":"Lip","year":"2012","journal-title":"Eur Heart J"},{"key":"3","doi-asserted-by":"publisher","first-page":"i4482","DOI":"10.1136\/bmj.i4482","article-title":"Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis.","volume":"35","author":"Emdin","year":"2016","journal-title":"BMJ"},{"key":"4","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1161\/01.cir.0000039105.49749.6f","article-title":"Lifetime risk for developing congestive heart failure: the Framingham Heart Study.","volume":"10","author":"Levy","year":"2002","journal-title":"Circulation"},{"key":"5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/0002-8703(86)90155-9","article-title":"Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population.","volume":"11","author":"Kannel","year":"1986","journal-title":"Am Heart J"},{"key":"6","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.","volume":"38","author":"Antman","year":"2014","journal-title":"Lancet"},{"key":"7","doi-asserted-by":"publisher","first-page":"afac146","DOI":"10.1093\/ageing\/afac146","article-title":"Impact of direct oral anticoagulant use on mortality in very old patients with non-valvular atrial fibrillation.","volume":"5","author":"Ito","year":"2022","journal-title":"Age Ageing"},{"key":"8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-022-01688-1","article-title":"Risk of heart failure in elderly patients with atrial fibrillation and diabetes taking different oral anticoagulants: a nationwide cohort study.","volume":"2","author":"Loh","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"9","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jphs.2018.07.002","article-title":"Factor Xa inhibition by rivaroxaban attenuates cardiac remodeling due to intermittent hypoxia.","volume":"13","author":"Hayashi","year":"2018","journal-title":"J Pharmacol Sci"},{"key":"10","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1093\/eurheartj\/ehz117","article-title":"Protease-activated receptor 2 deficiency mediates cardiac fibrosis and diastolic dysfunction.","volume":"4","author":"Wegner","year":"2019","journal-title":"Eur Heart J"},{"key":"11","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1161\/CIRCULATIONAHA.118.033544","article-title":"Protease-Activated Receptor-2 Plays a Critical Role in Vascular Inflammation and Atherosclerosis in Apolipoprotein E-Deficient Mice.","volume":"13","author":"Sata","year":"2018","journal-title":"Circulation"},{"key":"12","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1161\/ATVBAHA.117.310082","article-title":"PAR2 (Protease-Activated Receptor 2) Deficiency Attenuates Atherosclerosis in Mice.","volume":"3","author":"Owens AP","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"13","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jacbts.2021.09.010","article-title":"Rivaroxaban, a Direct Oral Factor Xa Inhibitor, Attenuates Atherosclerosis by Alleviating Factor Xa-PAR2-Mediated Autophagy Suppression.","volume":"6","author":"Sasano","year":"2021","journal-title":"JACC Basic Transl Sci"},{"key":"14","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jjcc.2015.05.018","article-title":"Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies.","volume":"6","author":"Ueda","year":"2015","journal-title":"J Cardiol"},{"key":"15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1177\/2048872618790561","article-title":"Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48.","volume":"8","author":"Giugliano","year":"2019","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"16","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1016\/j.jacc.2017.09.027","article-title":"Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction.","volume":"7","author":"McMurray","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"17","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.atherosclerosis.2015.03.023","article-title":"Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice.","volume":"24","author":"Sata","year":"2015","journal-title":"Atherosclerosis"},{"key":"18","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1538-7836.2007.02473.x","article-title":"Factor Xa or thrombin: is factor Xa a better target?","volume":"5","author":"Ansell","year":"2007","journal-title":"Journal of thrombosis and haemostasis : JTH"},{"key":"19","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2147\/VHRM.S49830","article-title":"Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment.","volume":"9","author":"Friedman","year":"2013","journal-title":"Vasc Health Risk Manag"},{"key":"20","first-page":"236","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy.","volume":"6","author":"Bri\u00ebt","year":"1993","journal-title":"Thromb Haemost"},{"key":"21","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1253\/circj.cj-66-0092","article-title":"Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013).","volume":"7","author":"JCS Joint Working Group","year":"2014","journal-title":"Circ J"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.206238","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T18:32:04Z","timestamp":1744309924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.206238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":21,"alternative-id":["206238"],"URL":"https:\/\/doi.org\/10.18632\/aging.206238","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]}}}